Citations

Clear

5 citation(s) found for "Shin, Eun Ji".

Endoscopic Ultrasound-Guided Gallbladder Drainage
Baron, Todd H., Umar, Shifa, Lam, Gregory, Pannala, Rahul , Amateau, Stuart, Tielleman, Thomas, Khodorskiy, Dmitriy O., Companioni, Rafael Ching, Bedi, Gurneet, Torres, Ricardo Marrero, Chudy‐Onwugaje, Kenechukwu, Bhogal, Neil, Gelrud, Andrés , Gabr, Moamen, Shin, Eun Ji, Adler, Douglas G., Irani, Shayan , Kushnir, Vladimir, Sachdev, Mankanwal S., Sharma, Neil, Tyberg, Amy , Widmer, Jessica, Widmer, Jessica L , Canakis, Andrew , Baron, Todd H. , Amateau, Stuart K. , Tielleman, Thomas , Companioni, Rafael A. Ching, Chudy‐Onwugaje, Kenechukwu , Gabr, Moamen , Shin, Eun Ji , Adler, Douglas G. , Kushnir, Vladimir , Sachdev, Mankanwal S. , Sharma, Neil

Mayo Clinic

Journal of Clinical Gastroenterology | July 23, 2026 | Volume: 60 | Issue: 8 | Pages: 685-694

10.1097/mcg.0000000000002409 | PMID 42490390 Get It

Acute cholecystitis affects ∼200,000 individuals annually in the United States, with laparoscopic cholecystectomy as the gold standard treatment. However, in high-risk surgical candidates, alternative drainage methods are necessary. Percutaneous transhepatic gallbladder drainage (PT-GBD) has traditionally served as the primary alternative intervention, offering rapid decompression, but is limited by a negative impact on the patient’s quality of life, the risk of long-term or even permanent tube placement, adverse events, and high recurrence rates. Endoscopic approaches, such as endoscopic transpapillary gallbladder drainage (ET-GBD) and, more recently, endoscopic ultrasound-guided gallbladder drainage (EUS-GBD), have emerged as viable alternatives to PT-GBD. EUS-GBD, first introduced in 2007, offers technical and clinical outcomes comparable to PT-GBD with fewer adverse events, shorter hospital stays, and lower rates of recurrence. The introduction of lumen-apposing metal stents (LAMS) has revolutionized EUS-GBD, simplifying deployment and enabling subsequent internal gallbladder access, which allows additional interventions such as cholecystoscopy and stone removal. EUS-GBD is now supported by international guidelines, and 1 device has achieved FDA approval for the management of acute cholecystitis in nonsurgical candidates. Proper patient selection is essential, guided by multidisciplinary evaluation, with EUS-GBD contraindicated in specific scenarios such as gallbladder perforation, coagulopathy, and large-volume ascites. Technical considerations include choice of access site (transgastric versus transduodenal), stent type, and procedural route [direct (freehand) or wire-guided]. Postprocedural care and stent management remain variable and nonstandardized. Emerging data suggest that interval cholecystectomy can still be performed safely after EUS-GBD. As adoption of EUS-GBD with LAMS expands, structured training and standardization of practice are crucial to optimizing outcomes.
Multifocal Cryoballoon Ablation for Eradication of Barrett's Esophagus-Related Neoplasia: A Prospective Multicenter Clinical Trial
Rosenblum, Michael , Dumot, John A. , Chak, Amitabh , Iyer, Prasad G. , Khara, Harshit S. , Corbett, F Scott , McKinley, Matthew , Shin, Eun Ji , Waxman, Irving , Infantolino, Anthony, Tofani, Christina , Samarasena, Jason , Chang, Kenneth J. , Wang, Bingkai , Goldblum, John R. , Voltaggio, Lysandra , Lightdale, Charles J. , Shaheen, Nicholas J. , Iyer, Prasad, Canto, Marcia Irene , Trindade, Arvind J. , Abrams, Julian A , Diehl, David L. , Montgomery, Elizabeth Anne

Mayo Clinic

American Journal of Gastroenterology | October 2, 2020 | Volume: 115 | Issue: 11 | Pages: 1879-1890

10.14309/ajg.0000000000000822 | PMID 33156107 Get It

INTRODUCTION: Ablation of Barrett's esophagus (BE) is the preferred approach for the treatment of neoplasia without visible lesions. Limited data on cryoballoon ablation (CBA) suggest its potential clinical utility. We evaluated the safety and efficacy of CBA in a multicenter study of patients with neoplastic BE. METHODS: In a prospective clinical trial, 11 academic and community centers recruited consecutive patients with BE of 1–6 cm length and low-grade dysplasia, high-grade dysplasia (HGD), or intramucosal adenocarcinoma (ImCA) confirmed by central pathology. Patients with symptomatic pre-existing strictures or visible BE lesions had dilation or endoscopic mucosal resection (EMR), respectively, before enrollment. A nitrous oxide cryoballoon focal ablation system was used to treat all visible columnar mucosa in up to 5 sessions. Study end points included complete eradication of all dysplasia (CE-D) and intestinal metaplasia (CE-IM) at 1 year. RESULTS: One hundred twenty patients with BE with ImCA (20%), HGD (56%), or low-grade dysplasia (23%) were enrolled. In the intention-to-treat analysis, the CE-D and CE-IM rates were 76% and 72%, respectively. In the per-protocol analysis (94 patients), the CE-D and CE-IM rates were 97% and 91%, respectively. Postablation pain was mild and short lived. Fifteen subjects (12.5%) developed strictures requiring dilation. One patient (0.8%) with HGD progressed to ImCA, which was successfully treated with EMR. Another patient (0.8%) developed gastrointestinal bleeding associated with clopidogrel use. One patient (0.8%) had buried BE with HGD in 1 biopsy, not confirmed by subsequent EMR. DISCUSSION: In patients with neoplastic BE, CBA was safe and effective. Head-to-head comparisons between CBA and other ablation modalities are warranted (clinicaltrials.gov registration NCT02514525).
Corrigendum to: Neural evidence for persistent attentional bias to threats in patients with social anxiety disorder
Kim, So-Yeon , Shin, Jung Eun , Lee, Yoonji Irene, Kim, Haena , Choi, Soo‐Hee , Jo, Hang Joon

Mayo Clinic

Social Cognitive and Affective Neuroscience | December 20, 2018 | Volume: 13 | Issue: 12 | Pages: 1327-1327

10.1093/scan/nsy115 | PMID 31222350 Get It

Neural evidence for persistent attentional bias to threats in patients with social anxiety disorder
Shin, Jung Eun , Lee, Yoonji Irene, Kim, Haena , Choi, Soo‐Hee , Jo, Hang Joon , Kim, So-Yeon

Mayo Clinic

Social Cognitive and Affective Neuroscience | November 14, 2018 | Volume: 13 | Issue: 12 | Pages: 1327-1336

10.1093/scan/nsy101 | PMID 30445473 Get It

MR staging accuracy for endometrial cancer based on the new FIGO stage
Shin, Kyung Eun , Park, Byung Kwan , Kim, Chan Kyo , Bae, Duk Soo, Song, Sang Yong, Kim, Bohyun, Kim, Bohyun

Mayo Clinic

Acta Radiologica | July 8, 2011 | Volume: 52 | Issue: 7 | Pages: 818-824

10.1258/ar.2011.100426 | PMID 21742787 Get It

Background Magnetic resonance imaging (MRI) has been frequently used to determine a preoperative treatment plan for gynecologic cancers. However, the MR accuracy for staging an endometrial cancer is not satisfactory based on the old FIGO staging system. Purpose To evaluate MR accuracy for staging endometrial cancer using the new FIGO staging system. Material and Methods Between January 2005 and May 2009, 199 women underwent surgery due to endometrial cancer. In each patient, an endometrial cancer was staged using MR findings based on the old FIGO staging system and then repeated according to the new FIGO staging system for comparison. Histopathologic findings were used as a standard of reference. Results The accuracy of MRI in the staging of endometrial carcinoma stage I, II, III, and IV using the old FIGO staging system were 80% (159/199), 89% (178/199), 90% (179/199), and 99% (198/199), respectively, compared to 87% (174/199), 97% (193/199), 90% (179/199), and 99% (198/199), respectively, when using the new FIGO staging criteria. The overall MR accuracy of the old and new staging systems were 51% (101/199) and 81% (161/199), respectively. Conclusion MRI has become a more useful tool in the preoperative staging of endometrial cancers using the new FIGO staging system compared to the old one with increased accuracy.